Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Research and development expenses, net $ 6,436 $ 2,858 $ 14,441 $ 8,458
General and administrative expenses 2,394 1,797 6,749 3,987
Operating loss 8,830 4,655 21,190 12,445
Financial expenses (income), net 5 (395) (248) (1,182)
Net Loss $ 8,835 $ 4,260 $ 20,942 $ 11,263
Basic and diluted loss per share of Common Stock $ 0.38 $ 2.69 $ 0.91 $ 7.37
Weighted average number of shares of Common Stock outstanding, basic and diluted 23,150,253 2,035,625 23,013,790 2,015,349